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Abstract 
 
Background: Over time, an evolution in the causes of morbidity and mortality among HIV-positive 
individuals has been reported. It is increasingly important to monitor trends in causes of death to 
devise appropriate prevention and management strategies. 
Methods: Individuals from the D:A:D Study were followed from January 1999 until death, loss-to-
follow-up or February 2011, whichever occurred first. Relative rates were calculated using Poisson 
regression. 
Results: There were 3,909 deaths in 49,731 individuals during 308,719 person-years 
(rate=12.7/1000 person-years; 95% CI 12.3-13.1). Leading underlying causes were: AIDS-related 
(28.7%), non-AIDS-defining cancers (15.1%), liver disease (13.2%) and cardiovascular disease 
(11.1%). Rates of all-cause death fell from 17.5/1000 person-years in 1999/2000 to 9.1 in 
2009/2011; similar trends were seen in death rates for AIDS-related (5.9-2.0), liver disease (2.7-
0.9) and cardiovascular disease (1.8-0.9). However, non-AIDS cancers death rates remained 
stable (1.6-2.1). Decreases in AIDS-related death rates were no longer evident after accounting for 
factors that changed over time, including CD4 cell count. However, all-cause, liver disease and 
cardiovascular disease death rates remained decreasing over time. The percentage of all deaths 
that were AIDS-related (34.0% in 1999/2000-22.5% in 2009/2011) and liver-related (15.6%-10.2%) 
decreased over time, whereas non-AIDS cancers increased (9.4%-22.7%). 
Conclusions: Recent reductions in rates of AIDS-related deaths are linked with continued 
improvement in CD4 cell count. We hypothesize that the markedly reduced rates of liver disease 
and cardiovascular disease deaths over time could be explained by improved use of non-HIV 
specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without 
any evidence of improvement. No other emerging trends in causes of unexpected deaths were 
observed. 
 
Funding: ‘Oversight Committee for The Evaluation of Metabolic Complications of HAART’ with 
representatives from academia, patient community, FDA, EMA and consortium of AbbVie, 
Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F. 
Hoffmann-La Roche and Janssen Pharmaceuticals 
 
Background 
 
In settings with access to antiretroviral therapy (ART), there have been dramatic reductions in 
AIDS-related mortality amongst HIV-positive individuals in care, with life expectancy now 
approaching that seen in the general population1-3. As a result, the relative importance of other 
traditionally non-AIDS related morbidities have increased, and a wider range of complications has 
been observed than in previous years1. 
Rates of some non-AIDS related morbidities may be expected to be higher than those seen in the 
general population for three main reasons. Firstly the HIV-positive population in resource-rich 
settings has a high level of traditional risk factors for non-AIDS morbidities, such as smoking and 
hepatitis co-infection4-6. Secondly, recent evidence suggests that the persistent immunodeficiency, 
immune dysregulation, immune activation and inflammation associated with HIV infection, 
including in patients on ART, may increase the risk of some of these morbidities7,8. Thirdly, 
antiretroviral-related adverse events, such as dyslipidamia and diabetes, may also play a role. 
Although one cannot dispute the clear benefits of ART, life-long exposure to these drugs is likely to 
be required. Thus, long-term surveillance for emerging, not-yet-identified serious adverse events 
caused by extended exposure to these novel agents is important. Reporting of such events using a 
passive clinician-initiated approach will likely be insensitive to detect emerging issues should they 
occur. A major aim of the D:A:D Study is to be able to identify whether there is any emerging 
serious toxicity linked with use of ART, as demonstrated by an increase in the rates of mortality 
either from a particular organ system, from cancers, or other, as yet unanticipated, causes. 
The aim of this project is to investigate trends over time in all-cause mortality and for specific 
causes of death in the period from 1999-2011 within the D:A:D Study. We examined whether any 
observed changes over time in death rates (overall and cause-specific) can be explained by 
changes in the characteristics of the HIV-positive population, including HIV immunological and 
virological status. Finally, we assessed whether any unexpected increases in rates of death from 
any specific cause emerged. 
 
Methods 
 
Verification and classification of causes of death 
Participants included were from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) 
Study9. It is a collaboration of 11 cohort studies following 49,731 HIV-1-infected individuals 
receiving care at 212 clinics in Europe, USA, and Australia. Further information on the study is 
available at http://www.cphiv.dk/DAD/About/tabid/106/Default.aspx. All participants were under 
active follow-up in their cohorts at the time of D:A:D enrolment. Prospective follow-up began from 
January 1999 onwards, regardless of ART status. Participants were recruited during three 
recruitment waves: 1999-2001, 2004, and 2010. All clinical outcomes, including deaths, are 
reported in real time. For 84% of all reported deaths, the sites provided a completed-case report 
form and so the cause of death could be centrally validated. Consistent classification categories for 
causes of death was used across the entire study period using adapted ICD-10 codes, with the 
Cause of Death (CoDe) form used from 2004 onwards (see www.cphiv.dk)10. 
 
Although data on both the underlying and other contributing causes of death are available, only the 
underlying cause is considered here and is referred to as ‘cause of death’ hereafter. They were 
grouped for analysis into the following five categories: AIDS-related; Cardiovascular disease 
related; Liver disease-related; Non-AIDS Cancers (i.e. excluding Kaposi’s sarcoma, non-Hodgkin 
lymphoma and cervical cancer); and Other/unknown. 
 
Statistical methods 
Individuals were followed from D:A:D entry to the first of death, six months after last clinic visit or 
1st February 2011. Although follow-up was available until 1st February 2012, the last year was 
excluded to account for underascertainment due to delayed reporting. 
Crude and age-standardised (adjusted to the age distribution of the cohort in 2003/2004, using 
Dobson’s approach to calculate corresponding confidence intervals11) death incidence rates were 
estimated for each two-year follow-up period. Unadjusted and adjusted relative rates (RRs) for the 
association of calendar time with all cause and cause-specific mortality were calculated using 
Poisson regression. Factors adjusted for  were: (fixed-time variables) age at study entry (per 5 
years), gender (male or female), ethnicity (white, black African or other), mode of HIV acquisition 
(men who have sex with men, heterosexual, intravenous drug user (IDU) or other/unknown) and 
(time-updated variables) hepatitis B virus (HBV) status (yes, no or unknown; defined as HBsAg 
positive, HBeAg positive or HBV DNA positive/anti-Hbe positive), hepatitis C virus (HCV) status 
(yes, no or unknown; defined as HCVAb positive), smoking status (current, former, ex-smoker or 
unknown), diabetes (yes or no; centrally validated endpoint; see www.cphiv.dk), hypertension (yes 
or no; defined as systolic blood pressure>140 mmHg; diastolic blood pressure>90 mmHg or 
receiving anti-hypertensives), HIV RNA viral load (VL; on ART with VL<400 copies/ml, on ART with 
VL≥400 copies/ml, off ART with VL<10,000 copies/ml or off ART with VL ≥10,000 copies/ml), body 
mass index (BMI; <18, 18 to ≤26, >26 to ≤30 or >30 kg/m2) and CD4 cell count (per 50 cells/mm3).  
All analyses were repeated, restricting to the person-years of follow-up amongst which study 
participants had viral load<400 copies/ml. This was to investigate trends over time in death rates 
amongst those with an optimal response to ART. Analyses were performed using SAS version 9.3 
(SAS Institute Inc., Cary, NC). 
 
Sensitivity analyses 
We remodelled all multivariable Poisson Regression models without adjusting for VL. Next, as 
individuals were censored at the time of death if they died from a cause other than the one under 
consideration, our primary analyses did not explicitly account for the presence of competing risks. 
This was investigated by excluding individuals who died from other causes from cause-specific 
analyses12. All analyses were remodelled according to the following demographic sub-groups: HBV 
status, HCV status, gender, HIV acquisition risk, smoking status, BMI and age group. Analyses 
were remodelled using multiple imputation to account for unknown causes of death, following the 
standard approach13. Finally, analyses were remodelled stratified by wave of recruitment into the 
D:A:D study. 
 
Role of the funding source 
The funders had no direct role in study design, data collection, analysis, interpretation, report 
writing, or the decision to submit for publication. The corresponding author had full access to all 
data and responsibility for submission for publication. 
 
Results 
 
Participant population 
The 49,731 D:A:D Study participants are summarized in Table 1. Most are male (74%), the most 
common mode of HIV acquisition was sex between men (44%), and the median age at study entry 
was 38 years. The median CD4 cell count at study entry was 400 cells/mm3 and 61% had ever 
received ART. Information on how the characteristics of the population have changed over time is 
also provided in Table 1. Compared to those who were under follow-up on 1st January 2001 (the 
time at which recruitment of the first wave of participants was nearing completion), those who were 
under follow-up in 2011 were less likely to have acquired HIV through intravenous drug use, less 
likely to be HBV or HCV positive, less likely to be a smoker, and more likely to have hypertension 
or diabetes. They were also more likely to be successfully treated on ART (with viral load<400 
copies/ml), had a higher median CD4 count and a longer median length of time spent on ART.  
A total of 3,909 deaths occurred. Compared to the general D:A:D population, there was a higher 
proportion of deaths in men, HCV positive individuals, those with an IDU risk for HIV acquisition, 
smokers and individuals with a previous AIDS diagnosis and the median CD4 cell count at study 
entry was lower (Table 1) 
 
Causes of death 
The most common cause of death observed over the whole study period was AIDS-related 
(28.7%), followed by non-AIDS cancers (15.1%), liver disease (13.2) and cardiovascular (11.1%; 
Table 2). The most common ‘other’ causes of death were invasive bacterial infection (6.6%) and 
suicide (3.8%). Although it has remained the most common cause over the whole follow-up period, 
the percentage of all deaths attributable to AIDS has fallen from 34.0% in 1999/2000 to 22.5% in 
2009-2011 (Figure 1; p<0.0001, chi-squared test). The percentage of liver-related deaths also fell 
(15.6% to 10.2%). In contrast, the proportion of all deaths that were from non-AIDS cancers has 
increased (9.4% to 22.7%). It is now the leading non-AIDS cause, and is equally as common as 
AIDS-related deaths. 
 
Rates of death over time 
The 3,909 deaths occurred over 308,719 person-years of follow-up (median 5.8 person-years; 
inter-quartile range 3.3, 9.9). This corresponds to a crude incidence mortality rate of 12.7 per 1,000 
person-years (95% confidence interval [CI] 12.3, 13.1). The rate of death has decreased from 17.5 
per 1,000 person-years in 1999/2000 to 9.1 in 2009-2011. This decline in overall death rate 
remains after accounting for an aging population through use of age-standardised estimates 
(Figure 2a and Supplementary Table 3). Similarly, declines were seen for AIDS-related, liver 
disease and cardiovascular deaths. In contrast, the rate of non-AIDS cancer deaths remained 
relatively constant, at 1.6 per 1000 person-years in 1999/2000 and 2.1 per 1000 person-years in 
2009-2011. This information was also reflected in the unadjusted rate ratios (Table 4).  
After adjusting for the potential confounders listed in the methods, the rate of all-cause mortality 
still declined (Table 4), suggesting that changes in these factors could not explain the decline in 
death rates seen over time. For example, compared to 1999/2000, the rate of death in 2009-2011 
was reduced by 28% (RR=0.72; 95% CI 0.61, 0.83). Similarly, liver disease and cardiovascular 
death rates were substantially reduced in later years even after accounting for changes in 
demographic factors over time. Compared to 1999/2000, rates of liver disease death in 2009-2011 
were 52% lower and rates of cardiovascular deaths were 67% lower. In contrast, changes in 
factors over time did explain much of the observed decline in rate of death from AIDS-related 
causes, as the adjusted RRs in Table 4 all approached one. Much of this was explained by 
improvements over time in the CD4 cell count; when this factor was not adjusted for in a post-hoc 
analyses the RRs were similar to those seen in the unadjusted analyses. Finally, adjustments for 
factors that may have changed over time did not affect the pattern for non-AIDS cancers, with rates 
remaining constant across the follow-up period. 
 
Sub-group of individuals with viral load<400 copies/ml 
There were 1859 deaths in 194,338 person-years of follow-up during which the current viral load 
was <400 copies/ml. As expected, this corresponded to a much lower overall death rate (9.6 per 
1000 person-years; 95% CI 9.1, 10.0), particularly from AIDS-related causes (rate=1.4; 95% CI 
1.2, 1.6). Figure 2b and Supplementary Table 5 display the age-adjusted and crude death rates 
from each specific cause over time. There was lower statistical power to explore trends over time, 
but there was no evidence of different trends compared to the main analysis. Furthermore, the 
adjusted rate ratios for changes in over time (Supplementary Table  6) found no evidence of an 
increasing trend from any cause, although confidence intervals are wider reflecting greater 
estimate uncertainty. 
Results were consistent in all sensitivity analyses performed, including the results of multiple 
imputation.  
 
Discussion 
 
Death rates amongst HIV-positive individuals with access to care and antiretroviral therapy across 
the study period have continued to decline. Currently, there is no indication of any increase in risk 
of death from any specific cause as a potential result of long term adverse effects of ART, and 
deaths from causes other than AIDS, cardiovascular disease, liver and non-AIDS cancers remain 
low. This provides continued evidence of the substantial net benefits of ART.  
It is notable that there have been apparent continued declines in mortality due to most causes, 
even after accounting for any effects of uncontrolled HIV replication, immunological improvements 
as measured by the CD4 count and age. This was reflected in the adjusted rate ratios displayed in 
Table 5, and the sub-group analysis considering those with current viral load<400 copies/ml. It is 
concerning however that the overall rate in non-AIDS Cancers has remained constant over time, 
and suggests that this is an important area that needs further research.  
A number of studies of HIV-positive populations have demonstrated dramatic decreases in AIDS-
related deaths over time1,14,15. It is encouraging that these improvements have continued into the 
most recent time period. The observed decline could be largely explained by changes in the CD4 
cell count, most likely as a result of successful ART rather than changes in included participants 
over time, as results were consistent when stratifying by recruitment wave. Any residual 
improvements not explained by the CD4 cell count may be due to better management of AIDS-
related conditions and increased use of prophylactic treatments. However, despite all of the 
improvements in AIDS-related morbidity, it remains the leading cause of death in this population16. 
Continued efforts to ensure good ART adherence and to diagnose more individuals at an earlier 
stage before the development of severe immunodeficiency are important to ensure that the low 
death rate from AIDS is sustained and potentially decreased even further17. 
Rates of death from non-AIDS cancer have remained stable over time, and is now the most 
common cause of non-AIDS deaths 1,15,16. Although there is evidence that non-AIDS cancers are 
associated with immunodeficiency and potentially HIV infection itself7,18, adjustment for CD4 cell 
count did not affect the association seen with calendar time (data not shown and 18), and the same 
trends were seen even when only considering those with controlled viral replication. Two 
alternative potential explanations for this stable death rate are an increase in non-AIDS cancer 
rates over time, but with improved patient management and therefore better prognosis, or 
alternatively a stable incidence rate with similar prognosis over time. Previous work suggests the 
latter scenario is most likely19. The impact of specific antiretroviral drugs on non-AIDS cancer rates 
is currently unknown and requires further study, although recent findings show an increased risk of 
anal cancer with increasing exposure to protease inhibitors20. It is important to note that HIV-
positive populations have a high prevalence of other risk factors, such as smoking, alcohol use, 
chronic viral hepatitis and other pro-oncogenic virus such as human papilloma virus (HPV)21,22,34,35. 
Reductions in the prevalence of these modifiable risk factors are likely required, along with early 
identification and improved management.  
The finding of a stable rate of death from non-AIDS cancer in our study is of concern when 
contrasted to the experience in the general population, where death rates have decreased in the 
same time period23,24 Although the spectrum of cancers may be very different, this suggests that 
any reduction in non-AIDS cancer death rates in the HIV-positive population will likely require more 
widespread use of the various interventions that apparently have been successfully used in the 
general population.  
We noted a decline in the rate of cardiovascular disease deaths during the study period of more 
than 65%, continuing the decline seen in earlier years in HIV-positive populations14. Although there 
has also been a decrease seen in the general population over the same time period, the 
magnitude of the reduction in the HIV-positive population seen here is of a substantially larger 
magnitude25. For example, in the European Region, age-standardised coronary heart disease 
death rates have fallen by less than 10%25. The decline observed in our study could not be 
attributed to changes over time in patient demographics, nor to changes in the CD4 cell count; 
indeed the percentage with hypertension, diabetes and high BMI increased over time. 
Furthermore, changes in the percentage with virological suppression did not explain the findings. 
This suggests that the decline could be a result of increased use of preventive interventions over 
the study period, such as smoking cessation, diet and exercise, lipid-lowering drugs and invasive 
procedures26. The observed reduction may also be as a result of better screening and earlier 
management, resulting in a reduction in CVD risk and incidence rates in later years. Furthermore, 
reduced utilisation of antiretrovirals traditionally associated with increased risk of CVD over the 
study period in favour of those with a better risk profile is also likely to have contributed to the 
observed decline. Awareness of potential associations between specific antiretrovirals with 
hyperlipidaemia (including protease inhibitors) and cardiovascular disease (including lopinavir and 
abacavir) has increased during the study period, and this is may have led to changes over time in 
targeted use of antiretrovirals according to cardiovascular risk profile33. 
There have been marked reductions in rates of liver-related deaths over the study period by more 
than 50%, continuing previously observed trends1,27. The number of liver-related deaths in 
individuals not co-infected with either HBV or HCV was very small, accounting for less than 5% of 
all liver-related deaths28. Thus, interventions to further reduce liver-related death should be 
targeted at the co-infected populations. Although much of the decline in death rates is likely 
attributable to the observed declines in the percentage with HBV or HCV, we observed that the 
trends in liver-related death were consistent when restricting analyses to co-infected individuals. 
Again, the reductions were not explained by changes over time in patient demographics in 
adjusted analyses. Furthermore, despite evidence that immunosuppression increases the risk of 
liver disease7, reduction in rates of liver deaths over time could not be explained by changes in the 
CD4 cell count. The known anti-HBV activity of the antiretrovirals lamivudine, emtricitabine and 
tenofovir and their increased use over time has likely contributed to the observed decline. In 
contrast, effective treatment for HCV remained relatively uncommon during the study period. 
However, the introduction of the new anti-HCV protease inhibitors and other direct-acting antiviral 
drugs should make anti-HCV treatment substantially more effective in eradicating the infection and 
this may lead to further reductions in the death rate from this cause29.  
A previous D:A:D study showed an 11% increased incidence rate of liver-related death per 
additional year of overall ART use, after adjusting for current CD4 cell count30. It is possible that 
certain antiretroviral drugs that were used more frequently in the early part of the study period, 
such as didanosine and stavudine31, may have adversely contributed to liver damage, an issue that 
we continue to explore. 
Monitoring of trends over time in specific causes of death is only possible if every effort is made to 
ascertain the vital status of all study participants. All contributing  study cohorts perform random 
monitoring of at least 10% of study participants’ clinical records to ensure  events are not missed. 
Careful ascertainment of cause of death is also imperative. Two recent studies demonstrated that 
large discrepancies in the assigned cause of death can occur according to the classification 
system used1,32. Therefore, initiatives such as the Coding Causes of Death in HIV project (CoDe) 
are vital10. This coding system enables consistency across HIV studies, accurate comparison of 
their findings, and also allows for cohort collaborations to examine rare causes of death16.  
Our study is observational, and so we cannot rule out the possibility or unmeasured confounding. 
Although every effort is taken to accurately classify deaths, there are occasions when insufficient 
documentation is available and they have to be classified as “unknown”. Of 3909 deaths in this 
study, 327 (8.4%) had available autopsy results. This highlights that autopsies can be a useful tool 
if the circumstances regarding a death are unclear. The wide geographical area covered helps to 
ensure the generalizability of the results, but if risk factors have varying importance in different 
settings some effects may be attenuated. Information on migrant status of study participants was 
not available. Finally, included individuals are from resource-rich countries, and results may not 
apply to other settings. 
Life-long therapy with potent antiretrovirals means that monitoring numbers of deaths from specific 
causes that have to date been rare is vital. This will ensure that any increases are identified at an 
early stage. The results of our study demonstrate that currently there is no indication of any 
increase in risk of death from any specific cause as a potential result of long-term adverse effects 
of ART, and deaths from causes other than AIDS, CVD, liver and non-AIDS cancer remain low.  
 
In summary, our study demonstrates that death rates have continued to decline amongst HIV-
positive individuals over the past decade. Despite dramatic reductions in rates of AIDS-related 
deaths, this remains the most common cause. Non-AIDS cancer deaths are now the most common 
non-AIDS cause, and incidence rates have remained constant over time. In contrast, incidence 
rates of liver-related and CVD-related deaths have decreased, suggesting improvements in 
prevention and patient management of these conditions. Collection of specific causes of death in 
HIV is important to identify any emerging trends in the overall death rate, or from any unexpected 
specific cause to allow earlier interventions in HIV case management. 
 
Putting research into context 
 
Systematic review: A review of studies that have also investigated trends over time in specific 
causes of death was performed using the PubMed search engine. Mesh Search terms were used, 
including the terms “HIV”, “death” and “” in the time period 1999-2013 to ensure that studies were 
considering trends over time in the recent antiretroviral era. Selection of potential references was 
made by reading manuscript titles and abstracts, before reading the full paper of those deemed 
relevant through the initial search. Studies of trends over time in the general population were made 
through a PubMed search using each of the terms “cardiovascular death”, “liver death” and “cancer 
death” with “calendar time”. 
 
What this study adds: This study has investigated the extent to which observed changes over time 
in cause-specific death rates can be attributed to concurrent changes in participant demographics, 
lifestyle factors, immunological status and presence co-morbidites such as HBV and HCV. 
Furthermore, it has investigated whether increases in numbers of deaths from specific causes that 
have to date been rare have occurred. This is vital to ensure that any increases are identified at an 
early stage and potential explanations, including antiretroviral-related toxicity, are investigated in a 
timely manner. Few studies of HIV positive individuals have sufficient sample sizes and detailed 
ascertainment of death to be able to address this question. 
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Universiteit van Amsterdam, Amsterdam: J.M. Prins*, T.W. Kuijpers, H.J. Scherpbier, K. Boer, 
J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. Reiss*, T. van der Poll, F.J.B. Nellen, J.M.A. 
Lange, S.E. Geerlings, M. van Vugt, S.M.E. Vrouenraets, D. Pajkrt, M. van der Valk. Academisch 
Ziekenhuis Maastricht, Maastricht: G. Schreij*, S. Lowe, A. Oude Lashof. Catharina-
ziekenhuis, Eindhoven: M.J.H. Pronk*, B. Bravenboer. Erasmus Medisch Centrum, Rotterdam: 
M.E. van der Ende*, T.E.M.S. de Vries-Sluijs, C.A.M. Schurink, M. van der Feltz, J.L. Nouwen, 
L.B.S. Gelinck, A. Verbon, B.J.A. Rijnders, L. Slobbe. Erasmus Medisch Centrum–Sophia, 
Rotterdam: N.G. Hartwig, G.J.A. Driessen. Flevoziekenhuis, Almere: J. Branger*. 
HagaZiekenhuis, Den Haag: R.H. Kauffmann*, E.F. Schippers. Isala Klinieken, Zwolle: P.H.P. 
Groeneveld*, M.A. Alleman, J.W. Bouwhuis. Kennemer Gasthuis: R.W. ten Kate*, R. Soetekouw. 
Leids Universitair Medisch Centrum, Leiden: F.P. Kroon*, P.J. van den Broek, J.T. van Dissel, 
S.M. Arend, C. van Nieuwkoop, M.G.J. de Boer, H. Jolink. Maasstadziekenhuis, Rotterdam: J.G. 
den Hollander*, K. Pogany. Medisch Centrum Alkmaar, Alkmaar: G. van Twillert*, W. Kortmann. 
Medisch Centrum Haaglanden, Den Haag: R. Vriesendorp*, E.M.S. Leyten. Medisch Spectrum 
Twente, Enschede: C.H.H. ten Napel*, G.J. Kootstra. Onze Lieve Vrouwe Gasthuis, 
Amsterdam: K. Brinkman*, W.L. Blok, P.H.J. Frissen, W.E.M. Schouten, G.E.L. van den Berk. 
Sint Elisabeth Ziekenhuis, Tilburg: J.R. Juttmann*, M.E.E. van Kasteren, A.E. Brouwer. Sint 
Lucas Andreas Ziekenhuis, Amsterdam: J. Veenstra*, K.D. Lettinga. Slotervaartziekenhuis, 
Amsterdam: J.W. Mulder*, E.C.M. van Gorp, P.M. Smit, S. Weijer. Stichting Medisch Centrum 
Jan van Goyen, Amsterdam: A. van Eeden*, D.W.M. Verhagen*. Universitair Medisch Centrum 
Groningen, Groningen: H.G. Sprenger*, R. Doedens, E.H. Scholvinck, S. van Assen, C.J. Stek. 
Universitair Medisch Centrum Sint Radboud, Nijmegen: P.P. Koopmans*, R. de Groot, M. 
Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, M. van der Flier, A.M. Brouwer, A.S.M. 
Dofferhoff. Universitair Medisch Centrum Utrecht, Utrecht: A.I.M. Hoepelman*, T. Mudrikova, 
M.M.E. Schneider, C.A.J.J. Jaspers, P.M. Ellerbroek, E.J.G. Peters, L.J. Maarschalk-Ellerbroek, 
J.J. Oosterheert, J.E. Arends, M.W.M. Wassenberg, J.C.H. van der Hilst. Vrije Universiteit 
Amsterdam, Amsterdam: S.A. Danner*, M.A. van Agtmael, J. de Vocht, R.M. Perenboom, F.A.P. 
Claessen, W.F.W. Bierman, E.V. de Jong, E.A. bij de Vaate. Wilhelmina Kinderziekenhuis, 
Utrecht: S.P.M. Geelen, T.F.W. Wolfs. Ziekenhuis Rijnstate, Arnhem: C. Richter*, J.P. van der 
Berg, E.H. Gisolf. Ziekenhuis Walcheren, Vlissingen: M. van den Berge*, A. Stegeman. 
Medisch Centrum Leeuwarden, Leeuwarden: D.P.F. van Houte*, M.B. Polée, M.G.A. van 
Vonderen. Sint Elisabeth Hospitaal, Willemstad - Curaçao: C. Winkel, A.J. Duits. 
Aquitaine Cohort (France): 
Composition of the GECSA: Coordination: F. Dabis*Epidemiology and Methodology: M. 
Bruyand, G. Chêne, F. Dabis, S. Lawson-Ayayi, R. Thiébaut. Infectious Diseases and Internal 
Medicine: F. Bonnal, F. Bonnet, N. Bernard, L. Caunègre, C. Cazanave, J. Ceccaldi, D. Chambon, 
I. Chossat, FA. Dauchy, S. De Witte, M. Dupon, P. Duffau, H. Dutronc, S. Farbos, V. Gaborieau, 
MC. Gemain, Y. Gerard, C. Greib, M. Hessamfar, D. Lacoste, P. Lataste, S. Lafarie, E. Lazaro, D. 
Malvy, JP. Meraud, P. Mercié, E. Monlun, P. Morlat, D. Neau, A. Ochoa, JL. Pellegrin, T. Pistone, 
JM. Ragnaud, MC. Receveur, S. Tchamgoué, MA. Vandenhende, JF. Viallard. Immunology: JF. 
Moreau, I. Pellegrin. Virology: H. Fleury, ME. Lafon, B. Masquelier, P. Trimoulet. Pharmacology: 
D. Breilh. Drug monitoring: F. Haramburu, G. Miremont-Salamé. Data collection and 
processing: MJ. Blaizeau, M. Decoin, J. Delaune, S. Delveaux, C. D’Ivernois, C. Hanapier, O. 
Leleux, B. Uwamaliya-Nziyumvira, X Sicard. Computing and Statistical analysis: S. Geffard, G. 
Palmer, D. Touchard. Scientific committee: F. Bonnet, M. Dupon, P. Mercié, P. Morlat, JL. 
Pellegrin, JM. Ragnaud, F. Dabis*. 
AHOD (Australian HIV Observational Database, Australia):  
Central coordination: M. Law* , K. Petoumenos, H. McManus, S. Wright, C. Bendall (Sydney, 
New South Wales); 
Participating physicians (city, state): R. Moore, S. Edwards, J. Hoy, K. Watson, N. Roth, J. 
Nicholson (Melbourne, Victoria); M Bloch, T. Franic, D. Baker, R. Vale, A. Carr, D. Cooper 
(Sydney, New South Wales); J. Chuah, M. Ngieng (Gold Coast, Queensland), D. Nolan, J. Skett 
(Perth, Western Australia). 
BASS (Spain): 
Central coordination: G. Calvo*, F. Torres, S. Mateu (Barcelona); 
Participating physicians (city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch, 
M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona). 
 
The Brussels St Pierre Cohort (Belgium):Coordination: S. De Wit*, N. Clumeck, M. Delforge, C. 
Necsoi. Participating physicians: N. Clumeck, S. De Wit*, AF Gennotte, M. Gerard, K. Kabeya, 
D. Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille, Y. Van Laethem. 
CPCRA (USA): 
Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr*, E. Krum, G. Thompson, D. 
Wentworth; 
Participating physicians (city, state): R. Luskin-Hawk (Chicago, Illinois); E. Telzak (Bronx, New 
York); W.M. El-Sadr (Harlem, New York); D.I. Abrams (San Francisco, California); D. Cohn 
(Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino (Houston, Texas); D. Mushatt 
(New Orleans, Louisiana); G. Friedland (New Haven, Connecticut); G. Perez (Newark, New 
Jersey); E. Tedaldi (Philadelphia, Pennsylvania); E. Fisher (Richmond, Virginia); F. Gordin 
(Washington, DC); L.R. Crane (Detroit, Michigan); J. Sampson (Portland, Oregon); J. Baxter 
(Camden, New Jersey). 
 
EuroSIDA (multinational) Coordinating Centre:: J Lundgren*#, O Kirk*, A Mocroft, A Cozzi-
Lepri, D Grint, D Podlekareva, J Kjær, L Peters, J Reekie, J Kowalska, J Tverland, A H Fischer, J 
Nielsen 
Participating countries and physicians:  
Argentina: (M Losso), C Elias, Hospital JM Ramos Mejia, Buenos Aires. 
Austria: (N Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical 
University Innsbruck, Innsbruck.  
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel 
State Medical University, Gomel; O Suetnov, Regional AIDS Centre, Svetlogorsk.  
Belgium: (N Clumeck), S De Wit*, M Delforge, Saint-Pierre Hospital, Brussels; R Colebunders, 
Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent.  
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo.  
Bulgaria: (K Kostov), Infectious Diseases Hospital, Sofia.  
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb.  
Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles 
University Hospital, Plzen.  
Denmark: (J Nielsen), G Kronborg,T Benfield, M Larsen, Hvidovre Hospital, Copenhagen; J 
Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C Pedersen, 
Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus. 
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond 
Siseklinik, Kohtla-Järve.  
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki.  
France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P Viard, Hôpital Necker-Enfants 
Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital Edouard Herriot, 
Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital de l'Archet, Nice; F Dabis*, 
D Neau, Unité INSERM, Bordeaux.  
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; 
J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, 
Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S Staszewski, JW Goethe University 
Hospital, Frankfurt; M Bickel, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, 
Cologne.  
Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; G Panos, 
A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration Genereal Hospital, 
Athens.  
Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest.  
Ireland: (F Mulcahy), St. James's Hospital, Dublin.  
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam 
Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem.  
Italy: (S Vella), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, Università 
Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, 
Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, 
University di Roma la Sapienza, Rome; A Chirianni, E Montesarchio, M Gargiulo, Presidio 
Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G Antonucci, A Testa, P Narciso, C Vlassi, M 
Zaccarelli, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A 
Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A 
d’Arminio Monforte, Istituto Di Clinica Malattie Infettive e Tropicale, Milan.  
Latvia: (B Rozentale), I Zeltina, Infectology Centre of Latvia, Riga.  
Lithuania: (S Chaplinskas), Lithuanian AIDS Centre, Vilnius.  
Luxembourg: (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.  
Netherlands: (P Reiss*), Academisch Medisch Centrum bij de Universiteit van Amsterdam, 
Amsterdam.  
Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.  
Poland: (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska, Centrum 
Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical University, Bialystok; A 
Boron-Kaczmarska, M Pynka, M Parczewski, Medical Univesity, Szczecin; M Beniowski, E 
Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical University, Gdansk; E 
Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz.  
Portugal: (F Antunes), M Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, Hospital 
de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest.  
Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; N Zakharova, St 
Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre for AIDS, Novgorod.  
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bratislava.  
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (J González-Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; S 
Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J 
Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i 
Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, 
Barcelona.  
Sweden: (A Karlsson), Venhaelsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University 
Hospital, Malmö.  
Switzerland: (B Ledergerber), R Weber*, University Hospital, Zürich; P Francioli, M Cavassini, 
Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, Hospital Cantonal 
Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University 
Hospital Basel.  
Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, Luhansk 
State Medical University; Luhansk; S Servitskiy, Odessa Region AIDS Center, Odessa; M Krasnov, 
Kharkov State Medical University, Kharkov.  
United Kingdom: (S Barton), St. Stephen's Clinic, Chelsea and Westminster Hospital, London; AM 
Johnson, D Mercey, Royal Free and University College London Medical School, London 
(University College Campus); A Phillips, MA Johnson, A Mocroft, Royal Free and University 
College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint 
Bartholomew's Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. 
Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General 
Hospital, Edinburgh. 
HivBivus (Sweden): 
Central coordination: L. Morfeldt*, G. Thulin, A. Sundström. 
Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L. 
Flamholc, C. Håkangård (Malmö). 
The ICONA Foundation (Italy): 
Governing Body: M. Moroni (Chair), A. Antinori, G. Carosi, R. Cauda, F. Chiodo, A. d’Arminio 
Monforte*, G Di Perri, M Galli, F. Ghinelli, R Iardino, G. Ippolito, A. Lazzarin, F. Mazzotta, R. 
Panebianco, G. Pastore, C.F. Perno 
Scientific Secretary: A. d’Arminio Monforte* 
Steering Committee: A. Ammassari, A. Antinori, C. Balotta, P. Bonfanti, M.R. Capobianchi, A. 
Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, A. d’Arminio Monforte*, A. De Luca, C. 
Gervasoni, E. Girardi, S. Lo Caputo, F Maggiolo, R. Murri, C. Mussini, M. Puoti, C. Torti 
Statistical and monitoring team: A Cozzi-Lepri, I Fanti, T Formenti  
Participating physicians and centres: M. Montroni, A. Giacometti, A Costantini, A. Riva 
(Ancona); U. Tirelli, F. Martellotta (Aviano-PN); G. Pastore, N. Ladisa, (Bari); F. Suter, F. Maggiolo 
(Bergamo); F. Chiodo, G. Verucchi, C. Fiorini (Bologna); G. Carosi, G. Cristini, C. Torti, C. Minardi, 
D. Bertelli (Brescia); T. Quirino, C Abeli (Busto Arsizio); P.E. Manconi, P. Piano (Cagliari); J 
Vecchiet, M. Farenga (Chieti); G Carnevale, S Lorenzotti (Cremona); F. Ghinelli, L. Sighinolfi 
(Ferrara); F. Leoncini, F. Mazzotta, M. Pozzi, S. Lo Caputo (Firenze); G. Pagano, G. Cassola, G 
Viscoli, A. Alessandrini, R. Piscopo, G Mazzarello (Genova); F. Soscia, L. Tacconi (Latina); A. 
Orani, R. Rossotto (Lecco); D Tommasi, P Congedo (Lecce); A. Chiodera, P. Castelli (Macerata); 
M Galli, A. Lazzarin, G. Rizzardini, I Schlacht, A. d’Arminio Monforte*, AL Ridolfo, A Foschi, A 
Castagna, S Salpietro, S. Merli, S. Melzi, M.C. Moioli, P Cicconi, T Formenti (Milano); R. Esposito, 
C. Mussini (Modena); A Gori (Monza), N. Abrescia, A. Chirianni, CM Izzo, M. De Marco, R. 
Viglietti, E Manzillo (Napoli); C. Ferrari, P. Pizzaferri (Parma); F Baldelli, G Camanni (Perugia); G. 
Magnani, M.A. Ursitti (Reggio Emilia); M. Arlotti, P. Ortolani (Rimini); R. Cauda, M Andreoni, A. 
Antinori, G. Antonucci, P. Narciso, V Tozzi, V. Vullo, A. De Luca, M. Zaccarelli, R. Acinapura, P. 
De Longis, M.P. Trotta, M. Lichtner, F. Carletti, (Roma); M.S. Mura, G Madeddu (Sassari); P. 
Caramello, G. Di Perri, G.C. Orofino, (Torino); E. Raise, F. Ebo (Venezia); G. Pellizzer, D. 
Buonfrate (Vicenza). 
Nice HIV Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, C. Caissotti.  
Participating physicians: P. Dellamonica, E. Bernard, E. Cua, F. De Salvador-Guillouet, J. 
Durant, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost, B. Prouvost-Keller, S. Pillet, P. 
Pugliese, V. Rahelinirina, P.M. Roger. 
Clinical research assistant: K. Dollet 
SHCS (Swiss HIV Cohort Study, Switzerland): Barth J, Battegay M, Bernasconi E, Böni J, Bucher 
HC, Burton-Jeangros C, Calmy A, Cavassini M, Cellerai C, Dubs R, Egger M, Elzi L, Fehr J, Flepp 
M, Francioli P (President of the SHCS), Furrer H, Fux CA, Gorgievski M, Günthard H, Hasse B, 
Hirsch HH, Hirschel B, Hösli I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H, 
Ledergerber B, Martinetti G, Martinez de Tejada B, Müller N, Nadal D, Pantaleo G, Rauch A, 
Regenass S, Rickenbach M, Rudin C, Schmid P, Schultze D, Schöni-Affolter F, Schüpbach J, 
Speck R, Taffé P, Telenti A, Trkola A, Vernazza P, von Wyl V, Weber R*, Yerly S. 
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Legends for Figures 
Figure 1 – Most common causes of death amongst HIV positive individuals, according to 
calendar year  
Figure 2 – Age-standardised incidence rates for specific causes of deaths according to 
calendar year (a) Amongst entire D:A:D Study population; (b) Amongst follow-up time spent 
with viral load <400 copies/ml 
 
Table 1 – Characteristics of study participants 
  Characteristics at D:A:D Study 
entry 
Characteristics of D:A:D participants under follow-up 
on: 
  All participants Died by last 
follow-up 
1st January 2001 1st January 2006 1st January 
2011 
Number  49731 (100%) 3909 (7.9%) 20863 (100%) 29497 (100%) 31938 (100%) 
Gender Male 36692 (73.8%) 3142 (8.6%) 15705 (75.3%) 21539 (73.0) 23502 (73.6) 
Age (years) Median (IQR) 38 (32, 45) 43 (37, 52) 39 (35, 46) 42 (37, 49) 46 (40, 53) 
Mode of HIV acquisition IDU 7628 (15.3%) 1159 (15.2%) 4350 (20.9%) 4535 (15.4) 3859 (12.1) 
 Heterosexual 16167 (32.5%) 856 (5.3%) 5654 (27.1%) 9846 (33.4) 11257 (35.3) 
 Othere 4025 (8.1%) 385 (9.6%) 1580 (7.6%) 2201 (7.5) 1984 (6.2) 
 MSM 21911 (44.1%) 1509 (6.9%) 9279 (44.5%) 12915 (43.8) 14838 (46.5) 
Known HCV positive
a
 
Yes 6447 (13.0%) 920 (14.3%) 3562 (17.1%) 2676 (9.1) 1977 (6.2) 
Known HBV positive
b
 
Yes 5431 (10.9%) 581 (10.7%) 2387 (11.4%) 3059 (10.4) 2599 (8.1) 
Smoking status Current 17224 (34.6%) 1584 (9.2%) 8880 (42.6%) 11716 (39.7) 12077 (37.8) 
 Former 8655 (17.4%) 753 (8.7%) 4062 (19.5%) 6093 (20.7) 7857 (24.6) 
 Never 12304 (24.7%) 611 (45.0%) 5109 (24.5%) 7215 (24.5) 3967 (12.4) 
 Unknown 11548 (23.2%) 961 (8.3%) 2812 (13.5%) 4473 (15.2) 8037 (25.2) 
BMI (kg/m
2
) 
Median (IQR) 23.0 (21.0, 25.3); 
n=42908 
22.3 (20.1, 24.7); 
n=3317 
23.0 (21.1, 25.3) 
n=13191 
23.2 (21.1, 25.7) 
n=21417 
23.8 (21.5, 
26.3) n=21003 
Hypertension
c
 
Yes 7863 (15.8%) 759 (9.7%) 2325 (11.1%) 6926 (23.5) 10176 (31.9) 
Diabetes
d
 
Yes 1362 (2.7%) 267 (19.6%) 368 (1.8%) 928 (3.2) 1470 (4.6) 
Total cholesterol (mmol/l) Median (IQR) 4.7 (4.0, 5.7); 
n=41603 
4.7 (3.8, 5.7); 
n=3205 
5.1 (4.2, 6.0) 
n=19207 
4.9 (4.1, 5.7) 
n=27443 
4.9 (4.2, 5.7) 
n=31253 
Previous AIDS diagnosis Yes 10482 (21.1%) 1484 (14.2%) 5316 (25.5%) 7888 (26.7) 8771 (27.5) 
CD4 cell count (cells/mm
3
) 
Median (IQR) 400 (242, 590); 
n=48548 
265 (111, 459); 
n=3799 
446 (286, 644) 
n=20804 
468 (320, 656) 
n=29338 
547 (400, 727) 
n=31909 
Currently on ART and Viral 
load <400 c/ml 
Yes 20802/47449 
(43.8%)e 
1429/3699 
(38.6%) e 
10874 (52.1%) 17940 (60.8%) 25640 (80.3%) 
Ever exposed to ART 
(years) 
n;  
Median (IQR) 
30430 (61.1%);  
2.9 (1.2, 4.8) 
2946 (9.7%);  
3.7 (1.9, 5.7) 
18120 (87%) 
3.3 (1.9, 5.0) 
24594 
6.2 (3.1, 8.7) 
29260 
7.9 (3.6, 12.6) 
Ever exposed to PI (years) n;  
Median (IQR) 
23072 (46.4%);  
2.2 (1.0, 3.2) 
2430 (10.5%);  
2.5 (1.3, 3.4) 
15008 (71.9%) 
2.5 (1.4, 3.3) 
19207 
3.5 (1.6, 6.2) 
21827 4.5 (2.0, 
8.5) 
Ever exposed to NNRTI 
(years) 
n;  
Median (IQR) 
14468 (29.1%);  
1.0 (0.4, 1.8) 
1413 (9.8%);  
0.9 (0.4, 1.6) 
8066 (38.7%) 
0.9 (0.4, 1.4) 
17048 
2.5 (1.0, 4.4) 
22256  
3.5 (1.4, 6.9) 
IQR=inter-quartile range; ART=antiretroviral therapy; PI=protease inhibitor; NNRTI=non nucleoside reverse transcriptase inhibitor; 
HBV=hepatitis B virus; HCV=hepatitis C virus; BMI=body mass index;c/ml=copies/ml 
aHCV antibody positive; bHBsAg positive, HBeAg positive or HBV DNA positive/anti-Hbe positive;c Systolic blood pressure>140 mmHg; 
Diastolic blood pressure>90 Hg; or receiving anti-hypertensives; d  Centrally validated endpoint: see www.cphiv.dk; eViral load not 
available for all pre-study entry
Table 2 – Specific causes of death in the D:A:D Study, 1999-2011 
 Number (%) 
Total deaths 3909 (100.0) 
AIDS-related 1123 (28.7) 
Liver-related 515 (13.2) 
Chronic viral hepatitis a 447 (11.4) 
Liver failure 68 (1.7) 
CVD-related 436 (11.1) 
MI, definite or possible 225 (5.9) 
Stroke 56 (1.4) 
Other CVD 60 (1.5)  
Other heart disease  86 (2.2) 
Complications due to diabetes 
mellitus 9 (0.2) 
Non-AIDS cancer b 590 (15.1)c 
Other/Unknown 1245 (31.8) 
Suicide 150 (3.8) 
Drug overdose 109 (2.8) 
Euthanasia 16 (0.4) 
Homicide 22 (0.6) 
Accident 74 (1.9) 
Invasive bacterial infection 259 (6.6) 
Lactic acidosis 17 (0.4) 
Pancreatitis 20 (0.5) 
Renal dysfunction/ disease 48 (1.2) 
Other 266 (5.8) 
Unknown 264 (6.8) 
a Includes liver cancers as a result of viral hepatitis-related liver failure; b Includes lung cancers, 
prostate cancers, anal cancers, head- and neck cancers, Hodgkin’s lymphomas, primary liver 
cancers (excluding hepatitis-related liver cancers, which are classified as “chronic viral hepatitis”), 
gastrointestinal cancers, breast cancers, uterus cancers, testicular cancers, penile cancers bladder 
cancers, kidney cancers, primary bone tumors, brain tumors (except non-Hodgkins´ lymphomas), 
unknown primary tumors and acute/chronic leukemias; c Most commonly reported cancers: lung 
(n=155), anal (38), head and neck (35), Hodgkins lymphoma (26)  
 
 
 
Supplementary Table 3 – Unadjusted (crude) and age-standardised mortality incidence rates for specific causes of death over 
calendar time 
  Incidence rate per 1000 person-years (95% confidence interval) 
 Total 
 
1999/2000 2001/2002 2003/2004 2005/2006 2007/2008 2009/2011 
Person-years follow-
up 
308719 14661 46426 54530 59490 64572 69040 
All-cause        
N 
Unadjusted 
3909 
12.7 (12.3, 
13.1) 
256 
17.5 (15.3, 
19.6) 
788 
17.0 (15.8, 
18.2) 
862 
15.8 (14.8, 
16.9) 
718 
12.1 (11.2, 
13.0) 
658 
10.2 (9.4, 
11.0) 
627 
9.1 (8.4, 
9.8) 
Age-standardised 12.2 (11.9, 
12.6) 
18.6 (16.3, 
21.1) 
17.6 (16.4, 
18.9) 
15.8 (14.8, 
16.9) 
11.6 (10.7, 
12.4) 
9.5 (8.8, 10.3) 8.0 (7.4, 
8.7) 
AIDS-related        
N 
Unadjusted 
1123 
3.6 (3.4, 3.9) 
87 
5.9 (4.7, 7.2) 
250 
5.4 (4.7, 6.1) 
278 
5.1 (4.5, 5.7) 
195 
3.3 (2.8, 3.7) 
172 
2.7 (2.3, 3.1) 
141 
2.0 (1.7, 
2.4) 
Age-standardised 3.6 (3.4, 3.8) 6.0 (4.8, 7.5) 5.5 (4.9, 6.3) 5.1 (4.5, 5.7) 3.2 (2.8, 3.7) 2.7 (2.3, 3.1) 2.0 (1.7, 
2.4) 
Liver-related        
N 
Unadjusted 
515 
1.7 (1.5, 1.8) 
40 
2.7 (1.9, 3.6) 
121 
2.6 (2.1, 3.1) 
105 
1.9 (1.6 2.3) 
102 
1.7 (1.4, 2.0) 
83 
1.3 (1.0, 1.5) 
64 
0.9 (0.7, 
1.2) 
Age-standardised 1.6 (1.5, 1.8) 2.9 (2.1, 4.0) 2.7 (2.2, 3.2) 1.9 (1.6 2.3) 1.7 (1.3, 2.0) 1.2 (0.9, 1.5) 0.8 (0.6, 
1.1) 
CVD-related        
N 
Unadjusted 
436 
1.4 (1.3, 1.5) 
26 
1.8 (1.1, 2.5) 
90 
1.9 (1.5, 2.3) 
97 
1.8 (1.4, 2.1) 
84 
1.4 (1.1, 1.7) 
79 
1.2 (1.0, 1.5) 
60 
0.9 (0.6, 
1.1) 
Age-standardised 1.3 (1.2, 1.5) 2.0 (1.3, 2.9) 2.0 (1.6, 2.5) 1.8 (1.4, 2.1) 1.3 (1.0, 1.6) 1.1 (0.9, 1.4) 0.7 (0.5, 
0.9) 
Non-AIDS cancera        
N 
Unadjusted 
590 
1.9 (1.8, 2.1) 
24 
1.6 (1.0, 2.3) 
86 
1.9 (1.5, 2.2) 
116 
2.1 (1.7 2.5) 
104 
1.7 (1.4, 2.1) 
118 
1.8 (1.5, 2.2) 
142 
2.1 (1.7, 
2.4) 
Age-standardised 1.8 (1.6, 1.9) 1.9 (1.2, 2.8) 2.0 (1.6, 2.5) 2.1 (1.7 2.5) 1.6 (1.3, 2.0) 1.6 (1.3, 1.9) 1.6 (1.3, 
1.9) 
Other known        
N 
Unadjusted 
981 
3.2 (3.0, 3.4) 
68 
4.6 (3.5, 5.7) 
207 
4.5 (3.9, 5.1) 
218 
4.0 (3.5, 4.5) 
184 
3.1 (2.6, 3.5) 
149 
2.3 (1.9, 2.7) 
155 
2.2 (1.9, 
2.6) 
Age-standardised 3.1 (2.9, 3.3) 5.0 (3.8, 6.4) 4.6 (4.0, 5.3) 4.0 (3.5, 4.5) 3.0 (2.6, 3.4) 2.2 (1.7, 2.4) 2.0 (1.7, 
2.4) 
Unknown        
N 
Unadjusted 
264 
0.9 (0.8, 1.0) 
11 
0.8 (0.3, 1.2) 
34 
0.7 (0.5, 1.0) 
48 
0.9 (0.6, 1.1) 
49 
0.8 (0.6, 1.1) 
57 
0.9 (0.7, 1.1) 
65 
0.9 (0.7, 
1.2) 
Age-standardised 0.8 (0.7, 0.9) 0.8 (0.4, 1.5) 0.7 (0.5, 1.0) 0.9 (0.6, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 
1.1) 
CI=confidence interval; CVD=cardiovascular disease 
95% CIs for unadjusted method calculated using a Normal approximation, unless there were fewer than 20 events, in which case the 
exact Poisson method was used. 95% CIs for age-standardised method calculated using Dobson’s approach 
a  Includes lung cancers, prostate cancers, anal cancers, head- and neck cancers, Hodgkin’s lymphomas, primary liver cancers (excluding 
hepatitis-related liver cancers, which are classified as “chronic viral hepatitis”), gastrointestinal cancers, breast cancers, uterus cancers, 
testicular cancers, penile cancers bladder cancers, kidney cancers, primary bone tumors, brain tumors (except non-Hodgkins´ 
lymphomas), unknown primary tumors and acute/chronic leukemias
Table 4–Incidence Rate ratios of underlying cause of death over calendar time 
 Incidence Rate ratio (95% confidence interval) of death 
 1999/ 2000 
(reference) 
2001/2002 2003/2004 2005/2006 2007/2008 2009-2011 
Total       
Unadjusted 1.0 0.97 (0.84, 
1.12) 
0.91 (0.79, 
1.04) 
0.69 (0.60, 
0.80) 
0.58 (0.51, 
0.67) 
0.52 (0.45, 
0.60) 
Adjusted a 1.0 1.07 (0.93, 
1.23) 
1.03 (0.90, 
1.19) 
0.81 (0.70, 
0.94) 
0.72 (0.62, 
0.84) 
0.72 (0.61, 
0.83) 
AIDS-related       
Unadjusted 1.0 0.91 (0.71, 
1.16) 
0.86 (0.68, 
1.09) 
0.55 (0.43, 
0.71) 
0.45 (0.35, 
0.58) 
0.34 (0.26, 
0.45) 
Adjusted a 
Adjusted, no CD4 b 
1.0 
1.0 
1.11 (0.87, 
1.42) 
1.09 (0.85, 
1.40) 
1.18 (0.92, 
1.50) 
1.11 (0.87, 
1.42) 
0.85 (0.65, 
1.10) 
0.75 (0.58, 
0.98) 
0.84 (0.64, 
1.09) 
0.68 (0.52, 
0.89) 
0.92 (0.70, 
1.22) 
0.63 (0.48, 
0.84) 
Liver-related       
Unadjusted 1.0 0.96 (0.67, 
1.37) 
0.71 (0.49, 
1.02) 
0.63 (0.44, 
0.91) 
0.47 (0.32, 
0.69) 
0.34 (0.23, 
0.50) 
Adjusted a 1.0 1.03 (0.71, 
1.49) 
0.81 (0.55, 
1.18) 
0.75 (0.51, 
1.10) 
0.61 (0.41, 
0.91) 
0.48 (0.32, 
0.74) 
CVD-related       
Unadjusted 1.0 1.09 (0.71, 
1.69) 
1.00 (0.65, 
1.55) 
0.80 (0.51, 
1.24) 
0.69 (0.44, 
1.07) 
0.49 (0.31, 
0.78) 
Adjusted a 1.0 1.02 (0.65, 
1.59) 
0.87 (0.56, 
1.36) 
0.64 (0.40, 
1.00) 
0.51 (0.32, 
0.81) 
0.33 (0.20, 
0.53) 
Non-AIDS cancer c       
Unadjusted 1.0 1.13 (0.72, 
1.78) 
1.30 (0.84, 
2.02) 
1.07 (0.69, 
1.66) 
1.12 (0.72, 
1.73) 
1.26 (0.82, 
1.94) 
Adjusted a 1.0 1.08 (0.68, 
1.70) 
1.18 (0.76, 
1.85) 
0.89 (0.56, 
1.40) 
0.90 (0.57, 
1.41) 
0.99 (0.63, 
1.55) 
Other/Unknown       
Unadjusted 1.0 0.96 (0.75, 
1.24) 
0.91 (0.70, 
1.16) 
0.73 (0.56, 
0.94) 
0.59 (0.46, 
0.77) 
0.59 (0.46, 
0.76) 
Adjusted a 1.0 1.07 (0.82, 
1.38) 
1.03 (0.80, 
1.33) 
0.86 (0.66, 
1.12) 
0.73 (0.56, 
0.96) 
0.77 (0.58, 
1.01) 
CVD=cardiovascular disease; Results from Poisson Regression Model 
aAdjusted for gender, age, ethnicity, risk for HIV acquisition, HBV status, HCV status, smoking status, diabetes, hypertension, current HIV 
RNA viral load, current BMI and current CD4 cell count; b Model adjusted for factors listed in a, except for current CD4 cell count, which 
was excluded from this model; c Includes lung cancers, prostate cancers, anal cancers, head- and neck cancers, Hodgkin’s lymphomas, 
primary liver cancers (excluding hepatitis-related liver cancers, which are classified as “chronic viral hepatitis”), gastrointestinal cancers, 
breast cancers, uterus cancers, testicular cancers, penile cancers bladder cancers, kidney cancers, primary bone tumors, brain tumors 
(except non-Hodgkins´ lymphomas), unknown primary tumors and acute/chronic leukemias
Supplementary Table 5 – Unadjusted (crude) and age-standardised mortality incidence rates for specific causes of death over 
calendar time amongst those on antiretroviral therapy with viral load<50 copies/ml 
  Incidence rate per 1000 person-years (95% confidence interval) 
 Total 
 
1999/2000 2001/2002 2003/2004 2005/2006 2007/2008 2009/2011 
Person-years follow-
up 
194338 7158 25663 31306 63240 42616 51355 
All-cause        
N 
Unadjusted 
1859 
9.6 (9.1, 10.0) 
72 
10.1 (7.7, 12.4) 
299 
11.7 (10.3, 
13.0) 
335 
10.7 (9.6, 11.8) 
329 
9.1 (8.1, 10.1) 
388 
9.1 (8.2, 10.0) 
436 
8.5 (7.7, 
9.3) 
Age-standardised 12.2 (11.9, 
12.6) 
10.6 (8.3, 13.4) 11.6 (10.3, 
13.0) 
10.0 (8.9, 11.1) 8.0 (7.1, 8.9) 7.7 (6.9, 8.5) 6.7 (6.0, 
7.4) 
AIDS-related        
N 
Unadjusted 
273 
1.4 (1.2, 1.6) 
14 
2.0 (1.1, 3.3) 
43 
1.7 (1.2, 2.2) 
53 
1.7 (1.2, 2.1) 
49 
1.4 (1.0, 1.7) 
49 
1.1 (0.8, 1.5) 
65 
1.3 (1.0, 
1.6) 
Age-standardised 1.3 (1.2, 1.5) 2.0 (1.1, 3.3) 1.7 (1.2, 2.2) 1.7 (1.2, 2.2) 1.3 (0.9, 1.7) 1.0 (0.7, 1.3) 1.1 (0.8, 
1.4) 
Liver-related        
N 
Unadjusted 
263 
1.4 (1.2, 1.6) 
12 
2.0 (1.1, 3.3) 
55 
1.7 (1.6, 2.7) 
46 
1.5 (1.0, 1.9) 
51 
1.4 (1.0, 1.8) 
53 
1.2 (0.9, 1.6) 
46 
0.9 (0.6, 
1.2) 
Age-standardised 1.8 (0.9, 3.2) 1.8 (0.9, 3.2) 2.2 (1.6, 2.8) 1.4 (1.0, 1.9) 1.3 (0.9, 1.7) 1.1 (0.8, 1.4) 0.7 (0.5, 
1.0) 
CVD-related        
N 
Unadjusted 
289 
1.5 (1.3, 1.7) 
9 
1.3 (0.6, 2.4) 
52 
2.0 (1.5, 2.6) 
60 
1.9 (1.4, 2.4) 
51 
1.4 (1.0, 1.8) 
66 
1.5 (1.2, 1.9) 
51 
1.0 (0.7, 
1.3) 
Age-standardised 1.3 (1.1, 1.4) 1.4 (0.6, 2.6) 2.0 (1.5, 2.7) 1.8 (1.3, 2.3) 1.1 (0.8, 1.5) 1.3 (1.0, 1.6) 0.7 (0.5, 
1.0) 
Non-AIDS cancera        
N 
Unadjusted 
401 
2.1 (1.9, 2.3) 
10 
1.4 (0.7, 2.6) 
46 
1.8 (1.3, 2.3) 
74 
2.4 (1.8 2.9) 
58 
1.6 (1.2, 2.0) 
93 
2.2 (1.7, 2.6) 
120 
2.3 (1.9, 
2.8) 
Age-standardised 1.7 (1.5, 1.9) 1.5 (0.7, 2.7) 1.8 (1.3, 2.4) 2.1 (1.7 2.7) 1.4 (1.0, 1.8) 1.8 (1.4, 2.2) 1.6 (1.3, 
1.9) 
Other known        
N 
Unadjusted 
489 
2.5 (2.3, 2.7) 
21 
2.9 (1.7, 4.2) 
91 
4.5 (3.9, 5.1) 
81 
3.5 (2.8, 4.3) 
99 
2.6 (2.0, 3.2) 
90 
2.7 (2.2, 3.3) 
107 
2.1 (1.7, 
2.5) 
Age-standardised 3.1 (2.9, 3.3) 3.1 (1.9, 4.7) 3.5 (2.8, 4.3) 2.4 (1.9, 3.0) 2.4 (2.0, 3.0) 1.9 (1.5, 2.3) 1.8 (1.4, 
2.2) 
Unknown        
N 
Unadjusted 
144 
0.7 (0.6, 0.9) 
6 
0.8 (0.3, 1.8) 
12 
0.5 (0.2, 0.7) 
21 
0.7 (0.4, 1.0) 
21 
0.6 (0.3, 0.8) 
37 
0.9 (0.6, 1.1) 
47 
0.9 (0.7, 
1.2) 
Age-standardised 0.6 (0.5, 0.8) 0.9 (0.3, 2.0) 0.5 (0.2, 0.8) 0.6 (0.4, 0.9) 0.5 (0.3, 0.8) 0.7 (0.5, 1.0) 0.8 (0.5, 
1.0) 
CI=confidence interval; CVD=cardiovascular disease 
95% CIs for unadjusted method calculated using a Normal approximation, unless there were fewer than 20 events, in which case the 
exact Poisson method was used. 95% CIs for age-standardised method calculated using Dobson’s approach. Estimates are age-
standardised to entire D:A:D population 
a  Includes lung cancers, prostate cancers, anal cancers, head- and neck cancers, Hodgkin’s lymphomas, primary liver cancers (excluding 
hepatitis-related liver cancers, which are classified as “chronic viral hepatitis”), gastrointestinal cancers, breast cancers, uterus cancers, 
testicular cancers, penile cancers bladder cancers, kidney cancers, primary bone tumors, brain tumors (except non-Hodgkins´ 
lymphomas), unknown primary tumors and acute/chronic leukemias
Supplementary Table 6 – Incidence Rate Ratios (RRs) of underlying cause of death over calendar time amongst those on 
antiretroviral therapy with viral load<50 copies/ml 
 Incidence Rate ratio (95% confidence interval) of death 
 1999/ 2000 
(reference) 
2001/2002 2003/2004 2005/2006 2007/2008 2009-2011 
Total       
Unadjusted 1.0 1.16 (0.90, 
1.50) 
1.06 (0.82, 
1.37) 
0.90 (0.70, 
1.16) 
0.91 (0.70, 
1.16) 
0.84 (0.66, 
1.08) 
Adjusted a 1.0 1.24 (0.95, 
1.61) 
1.10 (0.84, 
1.43) 
0.87 (0.66, 
1.13) 
0.84 (0.65, 
1.09) 
0.80 (0.62, 
1.04) 
AIDS-related       
Unadjusted 1.0 0.86 (0.47, 
1.57) 
0.87 (0.48, 
1.56) 
0.69 (0.38, 
1.25) 
0.59 (0.32, 
1.06) 
0.65 (0.36, 
1.15) 
Adjusted a 
Adjusted, no CD4 b 
1.0 
1.0 
0.98 (0.53, 
1.82) 
0.91 (0.49, 
1.68) 
1.02 (0.56, 
1.83) 
0.84 (0.46, 
1.54) 
0.79 (0.43, 
1.46) 
0.65 (0.35, 
1.21) 
0.67 (0.36, 
1.23) 
0.53 (0.29, 
0.99) 
0.89 (0.49, 
1.63) 
0.56 (0.31, 
1.03) 
Liver-related       
Unadjusted 1.0 1.28 (0.68, 
2.39) 
0.88 (0.46, 
1.65) 
0.84 (0.45, 
1.57) 
0.74 (0.40, 
1.39) 
0.53 (0.28, 
1.01) 
Adjusted a 1.0 1.44 (0.75, 
2.74) 
1.01 (0.52, 
1.97) 
0.95 (0.49, 
1.84) 
0.87 (0.45, 
1.68) 
0.67 (0.34, 
1.32) 
CVD-related       
Unadjusted 1.0 1.61 (0.79, 
3.27) 
1.52 (0.76, 
3.07) 
1.12 (0.55, 
2.27) 
1.23 (0.61, 
2.47) 
0.79 (0.39, 
1.60) 
Adjusted a 1.0 1.52 (0.74, 
3.12) 
1.27 (0.62, 
2.60) 
0.82 (0.39, 
1.69) 
0.82 (0.40, 
1.68) 
0.49 (0.23, 
1.02) 
Non-AIDS cancer c       
Unadjusted 1.0 1.28 (0.65, 
2.54) 
1.69 (0.87, 
3.27) 
1.15 (0.59, 
2.24) 
1.56 (0.81, 
3.00) 
1.67 (0.88, 
3.19) 
Adjusted a 1.0 1.30 (0.65, 
2.59) 
1.59 (0.81, 
3.12) 
0.96 (0.49, 
1.89) 
1.24 (0.64, 
2.42) 
1.34 (0.69, 
2.60) 
Other/Unknown       
Unadjusted 1.0 1.06 (0.70, 
1.63) 
0.86 (0.57, 
1.32) 
0.88 (0.58, 
1.33) 
0.79 (0.52, 
1.20) 
0.80 (0.53, 
1.20) 
Adjusted a 1.0 1.15 (0.74, 0.90 (0.58, 0.87 (0.56, 0.76 (0.49, 0.75 (0.49, 
1.77) 1.40) 1.34) 1.18) 1.16) 
CVD=cardiovascular disease; Results from Poisson Regression Model 
aAdjusted for gender, age, ethnicity, risk for HIV acquisition, HBV status, HCV status, smoking status, diabetes, hypertension, current HIV 
RNA viral load, current BMI and current CD4 cell count; b Model adjusted for factors listed in a, except for current CD4 cell count, which 
was excluded from this model; c Includes lung cancers, prostate cancers, anal cancers, head- and neck cancers, Hodgkin’s lymphomas, 
primary liver cancers (excluding hepatitis-related liver cancers, which are classified as “chronic viral hepatitis”), gastrointestinal cancers, 
breast cancers, uterus cancers, testicular cancers, penile cancers bladder cancers, kidney cancers, primary bone tumors, brain tumors 
(except non-Hodgkins´ lymphomas), unknown primary tumors and acute/chronic leukemia
 
